Verve Records releases a never-before-released live concert album from Ella Fitzgerald, recorded at the Oakland Coliseum on ...

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Verve Therapeutics (VERV) to $15 from $14 and keeps a Buy rating on ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Pharoah Sanders’ 'Love In Us All' and Bennie Maupin’s 'Slow Traffic To The Right' will both receive new vinyl pressings via Verve By Request.

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.69 per share a year ago. These figures ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose ...

Verve Therapeutics Inc. (VERV) on Thursday reported a loss of $50 million in its fourth quarter. The Boston-based company said it had a loss of 58 cents per share. The results beat Wall Street ...

A new album documents jazz legend Ella Fitzgerald in concert in Oakland, California, in 1967. The album is titled “The Moment ...